Kinetic modelling of serum S100b after traumatic brain injury

被引:74
作者
Ercole, A. [1 ]
Thelin, E. P. [2 ]
Holst, A. [3 ]
Bellander, B. M. [2 ]
Nelson, D. W. [4 ]
机构
[1] Univ Cambridge, Div Anaesthesia, Cambridge, England
[2] Karolinska Univ Hosp Solna, Karolinska Inst, Dept Clin Neurosci, Neurosurg Sect, Stockholm, Sweden
[3] KTH Royal Inst Technol, Sch Comp Sci & Commun, Stockholm, Sweden
[4] Karolinska Inst, Dept Physiol & Pharmacol, Sect Anesthesiol & Intens Care, Stockholm, Sweden
关键词
S100b protein; Human; Traumatic brain injury; Biomarkers; Kinetics; PROGNOSTIC BIOMARKER; CEREBROSPINAL-FLUID; PROTEIN; BLOOD; MARKER; S-100B; RELEASE; DAMAGE; HEAD; IMMUNOASSAY;
D O I
10.1186/s12883-016-0614-3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: An understanding of the kinetics of a biomarker is essential to its interpretation. Despite this, little kinetic modelling of blood biomarkers can be found in the literature. S100b is an astrocyte related marker of brain injury used primarily in traumatic brain injury (TBI). Serum levels are expected to be the net result of a multi-compartmental process. The optimal sample times for TBI prognostication, and to follow injury development, are unclear. The purpose of this study was to develop a kinetic model to characterise the temporal course of serum S100b concentration after primary traumatic brain injury. Methods: Data of serial serum S100b samples from 154 traumatic brain injury patients in a neurointensive care unit were retrospectively analysed, including only patients without secondary peaks of this biomarker. Additionally, extra-cranial S100b can confound samples earlier than 12 h after trauma and were therefore excluded. A hierarchical, Bayesian gamma variate kinetic model was constructed and the parameters estimated by Markov chain Monte Carlo sampling. Results: We demonstrated that S100b concentration changes dramatically over timescales that are clinically important for early prognostication with a peak at 27.2 h (95 % credible interval [25.6, 28.8]). Baseline S100b levels was found to be 0.11 mu g/L (95 % credible interval [0.10, 0.12]). Conclusions: Even small differences in injury to sample time may lead to marked changes in S100b during the first days after injury. This must be taken into account in interpretation. The model offers a way to predict the peak and trajectory of S100b from 12 h post trauma in TBI patients, and to identify deviations from this, possibly indicating a secondary event. Kinetic modelling, providing an equation for the peak and projection, may offer a way to reduce the ambiguity in interpretation of, in time, randomly sampled acute biomarkers and may be generally applicable to biomarkers with, in time, well defined hits.
引用
收藏
页数:8
相关论文
共 36 条
[1]   Multicenter evaluation of the analytical and clinical performance of the Elecsys® S100 immunoassay in patients with malignant melanoma [J].
Alber, B ;
Hein, R ;
Garbe, C ;
Caroli, U ;
Luppa, PB .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2005, 43 (05) :557-563
[2]   High serum S100B levels for trauma patients without head injuries [J].
Anderson, RE ;
Hansson, LO ;
Nilsson, O ;
Dijlai-Merzoug, R ;
Settergren, G .
NEUROSURGERY, 2001, 48 (06) :1255-1258
[3]  
[Anonymous], 2008, R LANG ENV STAT COMP
[4]   Serum S-100B and cleaved-tau are poor predictors of long-term outcome after mild traumatic brain injury [J].
Bazarian, Jeffrey J. ;
Zemlan, Frank P. ;
Mookerjee, Sohug ;
Stigbrand, Torgney .
BRAIN INJURY, 2006, 20 (07) :759-765
[5]   Systemic, local, and imaging biomarkers of brain injury: more needed and better use of those already established? [J].
Carpenter, Keri L. H. ;
Czosnyka, Marek ;
Jalloh, Ibrahim ;
Newcombe, Virginia E. J. ;
Helmy, Adel ;
Shannon, Richard J. ;
Budohoski, Karol P. ;
Kolias, Angelos G. ;
Kirkpatrick, Peter J. ;
Carpenter, Thomas Adrian ;
Menon, David K. ;
Hutchinson, Peter J. .
FRONTIERS IN NEUROLOGY, 2015, 6
[6]   Role of serum S100B as a predictive marker of fatal outcome following isolated severe head injury or multitrauma in males [J].
da Rocha, Adriana Brondani ;
Schneider, Rogerio Fett ;
de Freitas, Gabriel R. ;
Andre, Charles ;
Grivicich, Ivana ;
Zanoni, Caroline ;
Fossa, Aline ;
Gehrke, Junia T. ;
Jotz, Geraldo Pereira ;
Kaufmann, Mauro ;
Simon, Daniel ;
Regner, Andrea .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2006, 44 (10) :1234-1242
[7]  
DAVENPORT R, 1983, J NUCL MED, V24, P945
[8]   Functions of S100 Proteins [J].
Donato, R. ;
Cannon, B. R. ;
Sorci, G. ;
Riuzzi, F. ;
Hsu, K. ;
Weber, D. J. ;
Geczy, C. L. .
CURRENT MOLECULAR MEDICINE, 2013, 13 (01) :24-57
[9]   Using a cost-benefit analysis to estimate outcomes of a clinical treatment guideline: Testing the brain trauma foundation guidelines for the treatment of severe traumatic brain injury [J].
Faul, Mark ;
Wald, Marlena M. ;
Rutland-Brown, Wesley ;
Sullivent, Ernest E. ;
Sattin, Richard W. .
JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE, 2007, 63 (06) :1271-1278
[10]   On the release and half-life of S100B protein in the peripheral blood of melanoma patients [J].
Ghanem, G ;
Loir, B ;
Morandini, R ;
Sales, F ;
Lienard, D ;
Eggermont, A ;
Lejeune, F .
INTERNATIONAL JOURNAL OF CANCER, 2001, 94 (04) :586-590